Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 10/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | HSD11B2 | P80365 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14935729 | 0.85 | MEN1 (0.58) | MEN1MAPK1KMT2AHSD11B1EPHX2 | |
| SCHEMBL12578947 | 0.81 | HSD11B1 (0.56) | MEN1MAPK1KMT2AHSD11B1BTK | |
| SCHEMBL1847058 | 0.81 | HSD11B1 (0.56) | MEN1MAPK1KMT2AHSD11B1BTK | |
| SCHEMBL974114 | 0.81 | HSD11B1 (0.56) | MEN1MAPK1KMT2AHSD11B1BTK | |
| SCHEMBL1847057 | 0.81 | HSD11B1 (0.56) | MEN1MAPK1KMT2AHSD11B1BTK | |
| SCHEMBL974112 | 0.81 | HSD11B1 (0.56) | MEN1MAPK1KMT2AHSD11B1BTK | |
| SCHEMBL974113 | 0.81 | HSD11B1 (0.56) | MEN1MAPK1KMT2AHSD11B1BTK | |
| SCHEMBL13698839 | 0.80 | MEN1 (0.44) | MEN1MAPK1KMT2AHSD11B1EPHX2 | |
| SCHEMBL943516 | 0.80 | HSD11B1 (0.56) | MEN1MAPK1KMT2AHSD11B1EPHX2 | |
| SCHEMBL973696 | 0.80 | EPHX2 (0.45) | MEN1MAPK1KMT2AHSD11B1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536173-B2 | Tetrahydroquinoxaline urea derivatives as modulators of 11-B-hydroxysteroid dehydrogenase type I | SANOFI (FR) | 2013-09-17 | — | — | US | disclosed |
| US-20120165337-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165337-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | NR2C2, CBR3, NR0B2 | MEN1 3029/4885MAPK1 3338/4885KMT2A 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.